Ketamine use in power ache unsupported by proof, evaluate finds

The off-label use of ketamine to deal with power ache shouldn’t be supported by scientific proof, a brand new Cochrane evaluate has discovered.

Ketamine is an anesthetic generally used for procedural sedation and short-term ache aid. Ketamine can be often prescribed off-label to handle power ache situations akin to nerve ache, fibromyalgia and sophisticated regional ache syndrome. It’s one among a number of NMDA receptor antagonists—a gaggle of medicine thought to cut back ache by blocking sure mind receptors concerned in ache signaling.

The evaluate, performed by researchers from UNSW Sydney, Neuroscience Analysis Australia (NeuRA), and Brunel College of London, examined 67 trials involving over 2,300 grownup individuals. It assessed 5 NMDA receptor antagonists: ketamine, memantine, dextromethorphan, amantadine, and magnesium.

The outcomes, printed within the Cochrane Database of Systematic Critiques, present no clear proof of profit for ketamine in power ache and establish an elevated threat of opposed results akin to delusions, delirium, paranoia, nausea, and vomiting. Proof was rated low to very low certainty, as a result of small research sizes and poor methodological high quality.

“We need to be clear—we’re not saying ketamine is ineffective, however there’s lots of uncertainty,” mentioned Michael Ferraro, Doctoral Candidate at UNSW and NeuRA, first writer of the evaluate. “The info may level to a profit or no impact in any respect. Proper now, we simply do not know.”

Researchers seemed on the results throughout numerous power ache situations and dosing methods however discovered no clear proof of profit in any particular situation or dose. Unintended effects had been a significant concern, notably with intravenous use.

“The commonest opposed occasions we noticed had been psychotomimetic results akin to delusions, delirium and paranoia, in addition to nausea and vomiting,” mentioned Ferraro. “These results are distressing for a lot of sufferers. Clinicians usually attempt to stability the dose for ache aid with out triggering these signs, however this is not at all times achieved.”

The evaluate additionally discovered no research that reported on two key outcomes: whether or not ketamine lowered depressive signs or opioid use. That is notable, as ketamine is usually proposed for sufferers with depressive signs or opioid tolerance.

“This group of medicine, and ketamine particularly, are in comparatively frequent use for power ache around the globe. But now we have no convincing proof that they’re delivering significant advantages for individuals with ache, even within the quick time period,” mentioned Neil O’Connell, Professor at Brunel College of London, co-senior writer of the evaluate.

“That appears a superb cause to be cautious within the clinic and clearly signifies an pressing must undertake high-quality trials.”

The authors hope the evaluate will assist inform sufferers and clinicians weighing up potential advantages and harms, and information future analysis. Whereas extra proof is required, this evaluate highlights the significance of high-quality trials to grasp whether or not ketamine has a job in power ache care.

“We have seen the hurt that may come from taking medicines developed for acute ache and making use of them to power ache. Opioids are a major instance. Now we’re seeing the same sample with ketamine,” mentioned co-senior writer James McAuley, Professor at UNSW and senior researcher at NeuRA.

“As opioid prescribing is slowly lowered, there is a rising demand for options, however we should be cautious to not rush into widespread use with out robust proof.”

Supplied by
Cochrane